These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 30614479)

  • 41. [Supportive therapy and management of side effects in dermato-oncology].
    von Dücker L; Hüning S; Kähler K; Terheyden P; Nashan DRT
    Hautarzt; 2019 Dec; 70(12):975-988. PubMed ID: 31720719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Toxicity Management: Development of a Novel and Immune-Mediated Adverse Events Algorithm
.
    Mistry H; Forbes SG; Fowler N
    Clin J Oncol Nurs; 2017 Apr; 21(2 Suppl):53-59. PubMed ID: 28315558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immune-related adverse events of checkpoint inhibitors: an internist/general practitioner's point of view].
    Cisarovsky C; Kraege V; Obeid M; Garnier A
    Rev Med Suisse; 2020 Nov; 16(716):2264-2270. PubMed ID: 33237644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].
    Reinmuth N; Bitzer M; Deschler-Baier B; Fischer JR; Kuon J; Leipe J; Rawluk J; Schulz C; Heußel CP; Schultheiß M
    Dtsch Med Wochenschr; 2019 Mar; 144(5):346-353. PubMed ID: 30699440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

  • 46. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Adverse events of immune checkpoint inhibitors].
    Foller S; Oppel-Heuchel H; Fetter I; Winkler Y; Grimm MO
    Urologe A; 2017 Apr; 56(4):486-491. PubMed ID: 28246759
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characteristics of hospitalizations among patients receiving immune checkpoint inhibitors at a community teaching hospital.
    Rasor B; Henderson R; Chan K
    J Oncol Pharm Pract; 2020 Jan; 26(1):60-66. PubMed ID: 30924739
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The Use of Glucocorticoid in the Management of Adverse Effects Related to Immunocheckpoint Inhibitors].
    Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):615-620. PubMed ID: 31650942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recognition and management of the gastrointestinal and hepatic immune-related adverse events.
    Tan B; Li Y; Xu Y; Chen M; Wang M; Qian J
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):95-102. PubMed ID: 32077625
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy.
    Beardslee T; Draper A; Kudchadkar R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1275-1281. PubMed ID: 30124124
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Side effects of immunotherapy: a constant challenge for oncologists.
    Scotté F; Ratta R; Beuzeboc P
    Curr Opin Oncol; 2019 Jul; 31(4):280-285. PubMed ID: 30925538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Side effects of cancer immunotherapies : important role for the clinical immunologist].
    Obeid M
    Rev Med Suisse; 2019 Jan; 15(N° 632-633):17-19. PubMed ID: 30629360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Immune-related adverse events of immune checkpoint inhibitors].
    Tadano H; Torigoe T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic.
    Socinski MA
    Semin Oncol; 2015 Oct; 42 Suppl 2():S19-28. PubMed ID: 26477471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Immunotherapy is cancer treatment with a novel side-effect profile].
    Kondrup M; Raunkilde L; Svane IM; Schmidt H; Bastholt L
    Ugeskr Laeger; 2017 Oct; 179(40):. PubMed ID: 28992844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.
    Demlova R; Valík D; Obermannova R; ZdraŽilová-Dubská L
    Physiol Res; 2016 Dec; 65(Suppl 4):S455-S462. PubMed ID: 28006927
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of immunotherapy toxicities in older adults.
    Bhandari S; Gill AS; Perez CA; Jain D
    Semin Oncol; 2018 Aug; 45(4):226-231. PubMed ID: 30446167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.